Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS-314d-MR in Pulmonary Arterial Hypertension
NCT01458236Phase 3Withdrawn
- Sponsor
- Lung Biotechnology PBC
- Start
- Nov 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of esuberaprost in pulmonary arterial hypertension (PAH), sponsored by Lung Biotechnology PBC. Planned start Nov 2011; status: withdrawn.
02
Drugs
esuberaprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01458236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458236.